Catonsville, Maryland Clinical Trials

A listing of Catonsville, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 62 clinical trials
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

headache
preventive medication
treatment regimen
migraine
ly573144
PharmaSite Research Inc
 (6.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +162 other locations
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression

This study will evaluate whether a lifestyle intervention focused on weight loss, EMPOWER, reduces prostate cancer progression at 12 months among men with biochemical recurrence following local treatment for prostate cancer. Half of the men will be randomized to receive the EMPOWER intervention, while the other half will receive standard …

prostate cancer
bone scan
cancer
local therapy
serum testosterone
Johns Hopkins University
 (7.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

drug test
cancer
blood test
lung cancer
solid tumor
Maryland Oncology Hematology /ID# 214131
 (9.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +38 other locations
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

iobenguane
refractory hepatoblastoma
recurrent childhood rhabdomyosarcoma
platelet count
pediatric
Sinai Hospital of Baltimore
 (5.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +82 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

nf2 gene
schwartz
neutrophil count
crizotinib
neurofibroma
Johns Hopkins University (Site 250)
 (7.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +16 other locations
Ablation Versus Medical Management of Atrial Fibrillation in HFpEF

This is a prospective non-blinded randomized control pilot study comparing the effect of pulmonary vein isolation against medical management of atrial fibrillation in patients with Heart Failure with preserved Ejection Fraction (HFpEF).

atrial fibrillation
left ventricular hypertrophy
diuretic therapy
pro-brain natriuretic peptide
hypertrophy
Johns Hopkins Hospital
 (7.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work in treating patients with pneumonitis that does not respond to steroid treatment. Immunotherapy with monoclonal antibodies such as, infliximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow …

malignant solid neoplasm
bilateral oophorectomy
steroid treatment
solid tumor
hematopoietic and lymphoid cell neoplasm
Jarushka Naidoo
 (9.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Effects of tDCS on Apraxia of Speech in Non-Fluent Primary Progressive Aphasia

Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. There are three different variants of PPA, each a relatively distinct speech and language profile. For individuals with non-fluent variant PPA (nfvPPA), a core symptom is apraxia of speech (AOS), which is defined as an …

neurodegeneration
language testing
apraxia of speech
aphasia
transcranial direct current stimulation
Johns Hopkins Hospital
 (7.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer

A single-arm, two-stage, open-label, phase 2 study investigating the safety and efficacy of intravesical gemcitabine/docetaxel for bacillus Calmette-Guerin (BCG)-nave patients with non-muscle invasive bladder cancer (NMIBC). All participants will receive an induction course of gemcitabine/docetaxel instillations followed by maintenance instillations if initial efficacy is seen. In addition to providing initial …

recurrent tumor
bilateral oophorectomy
bilateral salpingectomy
combined modality therapy
bcg vaccine
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
 (7.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

combined modality therapy
cancer
castration-resistant prostate cancer
taxane
docetaxel
Johns Hopkins University
 (7.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +21 other locations